Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

718.36 -4.44 (-0.61%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

How Is The Market Feeling About Regeneron Pharmaceuticals? ↗

July 17, 2025

Via Benzinga

1 Healthcare Stock on Our Buy List and 2 to Brush Off

July 15, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

Assessing Regeneron Pharmaceuticals: Insights From 26 Financial Analysts ↗

July 10, 2025

Via Benzinga

1 Cash-Heavy Stock to Own for Decades and 2 to Ignore

July 08, 2025

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Via StockStory

23andMe’s $305M Sale To Co-Founder Wojcicki Approved: California Loses Legal Battle Over DNA Privacy ↗

July 07, 2025

A U.S. bankruptcy judge ruled that California's appeal to block the deal was unlikely to succeed, rejecting claims that the sale violated state genetic privacy laws.

Via Stocktwits

Topics Bankruptcy

Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗

July 07, 2025

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.

Via Investor's Business Daily

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 07, 2025

Via Investor Brand Network

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 07, 2025

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

2 Beaten-Down Stocks to Buy and Hold ↗

July 05, 2025

Via The Motley Fool

Topics Death

REGENERON PHARMACEUTICALS (NASDAQ:REGN) - A Potential Undervalued Biotech Stock ↗

July 04, 2025

REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers strong profitability, financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector.

Via Chartmill

Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma ↗

July 03, 2025

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

Via Benzinga

Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps ↗

July 02, 2025

While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory...

Via Stocktwits

Topics Death

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

July 02, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

July 01, 2025

Via Benzinga

Regeneron Pharmaceuticals Unusual Options Activity For July 01 ↗

July 01, 2025

Via Benzinga

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

June 28, 2025

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

Via MarketBeat

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

June 26, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

1 Profitable Stock for Long-Term Investors and 2 to Question

June 26, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday? ↗

June 25, 2025

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

Via Benzinga

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

June 24, 2025

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

June 22, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

June 20, 2025

Via Benzinga

FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder ↗

June 20, 2025

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.

Via Benzinga

Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull ↗

June 20, 2025

The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation.

Via Stocktwits

Topics Supply Chain

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

June 20, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss ↗

June 18, 2025

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Via Stocktwits

Topics Death

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗

June 18, 2025

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.

Via Benzinga

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

June 15, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025 ↗

June 15, 2025

These two S&P 500 stocks, which fell between 18.2% and 26.6% in May, are worth watching.

Via The Motley Fool

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.